{
    "Rank": 331,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT03447886",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "17-581"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "U54CA156732",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/U54CA156732"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Dana-Farber Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds",
                "OfficialTitle": "Understanding Barriers to Initiation and Adherence to Adjuvant Endocrine Therapy in Young Breast Cancer Survivors of Diverse Racial, Ethnic, and Socio-economic Backgrounds: The EMPOWER Study"
            },
            "StatusModule": {
                "StatusVerifiedDate": "June 2021",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "March 9, 2018",
                    "StartDateType": "Actual"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "August 27, 2018",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "August 27, 2018",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "February 21, 2018",
                "StudyFirstSubmitQCDate": "February 21, 2018",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "February 27, 2018",
                    "StudyFirstPostDateType": "Actual"
                },
                "LastUpdateSubmitDate": "June 9, 2021",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 11, 2021",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Rachel Freedman, MD, MPH",
                    "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Dana-Farber Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Dana-Farber Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "No",
                "IsFDARegulatedDrug": "No",
                "IsFDARegulatedDevice": "No"
            },
            "DescriptionModule": {
                "BriefSummary": "The overall goal of this study is to qualitatively explore how behavioral, cultural, psychosocial, and economic barriers and facilitators affect the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer",
                "DetailedDescription": "A qualitative study that will use interviews to gain an in depth understanding of factors affecting the decision to start and adhere to endocrine therapy (ET) among young breast cancer survivors of diverse racial, ethnic, and socio-economic backgrounds with hormone receptor positive (HR+) breast cancer"
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "Breast Cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Observational",
                "PatientRegistry": "No",
                "DesignInfo": {
                    "DesignObservationalModelList": {
                        "DesignObservationalModel": [
                            "Other"
                        ]
                    },
                    "DesignTimePerspectiveList": {
                        "DesignTimePerspective": [
                            "Other"
                        ]
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "17",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Quality Of Life",
                            "ArmGroupDescription": "This study uses qualitative research methods, specifically semi-structured interviews.\n\nThis will include moderator guide development,\nPhone interviews with breast cancer survivors will be conducted\nQualitative data analysis of the phone interviews will be conducted",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Other: Phone interview"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Other",
                            "InterventionName": "Phone interview",
                            "InterventionDescription": "Collecting clinical and socio-demographic information.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Quality Of Life"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Decision-making around endocrine therapy in young women with HR+ breast cancer.",
                            "PrimaryOutcomeDescription": "Open ended questions",
                            "PrimaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        }
                    ]
                },
                "SecondaryOutcomeList": {
                    "SecondaryOutcome": [
                        {
                            "SecondaryOutcomeMeasure": "Barriers and challenges to endocrine therapy adherence",
                            "SecondaryOutcomeDescription": "Open ended questions",
                            "SecondaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Social support",
                            "SecondaryOutcomeDescription": "Open ended questions",
                            "SecondaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Health behaviors",
                            "SecondaryOutcomeDescription": "Open ended questions",
                            "SecondaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Endocrine therapy adherence intervention preferences",
                            "SecondaryOutcomeDescription": "Open ended questions",
                            "SecondaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Health literacy",
                            "SecondaryOutcomeDescription": "Brief Health Literacy Screener (Chew items)",
                            "SecondaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        },
                        {
                            "SecondaryOutcomeMeasure": "Menopausal symptoms",
                            "SecondaryOutcomeDescription": "BCPT Symptom Checklist",
                            "SecondaryOutcomeTimeFrame": "3 months-3 years post active treatment"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "Inclusion Criteria:\n\nAre Hispanic, Latina, Black, or identify as socio-economically disadvantaged (any racial/ethnic background) as measured by an item of financial distress answering that they are \"having difficulty paying the bills no matter what they do\" to a question about their current household financial situation.18, 19\nreport a history of Stage 1-3 breast cancer\nreports HR+ breast cancer and confirm that they have had a discussion with their doctor about adjuvant ET; OR indicate that they are taking ET, even if they do not know their HR status, answer they are HR-, or do not recall having a discussion about ET)\nnot in active treatment (e.g., chemotherapy, radiation), with the exception of Herceptin\nat least 3 months, but no more than 3 years out of completion of active treatment\nno evidence of recurrent/metastatic disease\nat least 18, but< 45 years of age at diagnosis of first invasive breast cancer\nEnglish or Spanish speaking\nare willing to consent to the interview\n\nExclusion Criteria:\n\nHR- breast cancer and indicate they are not taking ET\nHR+ breast cancer but do not confirm discussion of ET or indicate they are taking ET\nStage 0 (DCIS) breast cancer\nRecurrent or metastatic disease\nLess than 3 months or more than 3 years post-active treatment\nLess than 18 years old or \u226545 years old at diagnosis",
                "HealthyVolunteers": "Accepts Healthy Volunteers",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "45 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult"
                    ]
                },
                "StudyPopulation": "Women of all races",
                "SamplingMethod": "Probability Sample"
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Rachel A Freedman, MD, MPH",
                            "OverallOfficialAffiliation": "Dana-Farber Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Dana Farber Cancer Institute",
                            "LocationCity": "Boston",
                            "LocationState": "Massachusetts",
                            "LocationZip": "02215",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            },
            "IPDSharingStatementModule": {
                "IPDSharing": "No"
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        }
                    ]
                }
            }
        }
    }
}